NYC Skyline BW

DEALS

Asalyxa

Asalyxa

Open

Health Care, Anti-Inflammatory

series A

First-in-class treatment for respiratory distress syndrome led by Orange Grove

$10mm

Raising

$7mm

$16.9bn by 2027

Global ARDS TAM

7.2%

CAGR

Left In the Round

Backed By:

About Asalyxa

Backed by MidWest based biotech VC and incubator Orange Grove Bio, Asalyxa is a clinical stage biotechnology company. Asalyxa has developed a drug platform targeting acute respiratory distress syndrome (ARDS), to which there is currently no treatment and a 40% mortality rate. They are also targeting traumatic brain injury and arthritis.

COVID-19 Long haulers could also greatly benefit from this drug. Aside from improved patient outcomes (i.e., eliminating mortality), ASX-100 will capture value by disrupting ICU stays often in excess of $400k on average per patient.

$7M is left in the Series A round led by Orange Grove Bio. Minimum check size is $150k. The company anticipates a $250M IPO in the next 2 years.